标签归档：ramucirumab

Ramucirumab(Synonyms: 雷莫芦单抗)

发表于由

Ramucirumab;(Synonyms: 雷莫芦单抗) 纯度: 99.40%

Ramucirumab 是人 VEGFR-2 拮抗剂，具有抗实体瘤作用。Ramucirumab 是一种人源化单克隆抗体，可与 VEGFR-2 结合，阻止 VEGFR 配体 VEGF-A，VEGF-C 和 VEGF-D 结合。

Ramucirumabamp;;(Synonyms: 雷莫芦单抗)

Ramucirumab Chemical Structure

CAS No. : 947687-13-0

规格 价格 是否有货 数量
1 mg ￥4000 In-stock
5 mg ￥9900 In-stock
25 mg 询价
50 mg 询价

* Please select Quantity before adding items.

生物活性

Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors[1]. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D[2].

IC50 Target[1][2]

VEGFR-2

;

Clinical Trial

分子量

143609.63

Formula

C6374H9864N1692O1996S46
CAS 号

947687-13-0
中文名称

雷莫芦单抗
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015 Mar;8(Spec Feature):49-53.

    [2]. Oholendt AL, et al. Ramucirumab: A New Therapy for Advanced Gastric Cancer. J Adv Pract Oncol. 2015 Jan-Feb;6(1):71-5.